Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

China: A recent study published in the Journal of Diabetes and its Complications highlighted dapagliflozin's (DAPA) ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Consultant in endocrinology and diabetes Professor Vinod Patel discusses current recommended pharmacological treatment ...

Lexicon (LXRX) announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual ...

Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...

This finding is especially interesting because the same drug was less effective at lowering blood sugar levels in older ...

Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ...

The prevalence of diabetes is increasing faster in some low-income countries than elsewhere in the world, generating concerns ...